In early May 2026, Albert Bourla, CEO of Pfizer, wrote directly to Friedrich Merz, the German Chancellor. The letter was not a routine lobbying communication. It was a warning: the cumulative weight of European pricing policy — AMNOG reference pricing, MFN benchmarking, EU HTA reform — was making Germany an increasingly unattractive launch market for innovative medicines. Novartis CEO Vas Narasimhan echoed the same message. AstraZeneca's Pascal Soriot had been making the case publicly for months.
Eli Lilly and Boehringer Ingelheim had already acted — withdrawing products from German tendering processes rather than accept prices that would anchor their global reference baskets. The withdrawal of a product from a major EU5 market is not a negotiating tactic. It is a signal that the maths no longer works.
The pharma backlash to German reforms is not sentiment. It is the market giving advance notice of what comes next — and what comes next is structural, not cyclical.
The feedback loop most teams are not pricing in
Most market access teams understand MFN in isolation: the US government uses European reference prices as a ceiling for Medicare negotiation. A lower European price means a lower US ceiling. The implication is linear and well-understood.
What is less well-understood is the compounding effect when MFN and EU HTA reform operate simultaneously.
"A weaker European deal doesn't stay in Europe. It weakens every future US negotiation. The two pricing regimes are no longer independent variables."
EU HTA reform — specifically the Joint Clinical Assessment (JCA) — has changed when European access strategy must begin, what evidence standard it must meet, and which markets are linked in assessment. JCA creates a single comparative evidence standard across participating member states. A weak JCA submission doesn't just cost you Germany or France — it affects the entire reference basket from which MFN draws.
This is the feedback loop: European HTA outcomes feed European prices. European prices feed MFN reference baskets. MFN reference baskets set the ceiling for US Medicare negotiation. A suboptimal evidence package in Brussels becomes a pricing constraint in Washington.
The three MFN mechanisms now in play
It is worth being specific about the policy architecture, because the three MFN pilots operate differently and carry different exposure profiles.
Active MFN Mechanisms — June 2026
GLOBE and GUARD are not proposals. They are active mandatory mechanisms. If your asset falls within the therapeutic class thresholds, the European price you accept today is the ceiling the US government will reference tomorrow. The sequencing of your European launch — which markets, in what order, at what price — is now a US commercial decision as much as a European one.
The access picture is already deteriorating
The EFPIA WAIT Indicator 2025 makes the direction of travel clear. Median time to patient access across the EU: 532 days from EMA approval. Proportion of new medicines not reaching all EU patients within two years of approval: 35%. These numbers have not improved. They have worsened, year on year, as the policy environment has become more complex and the commercial calculus of EU launch has shifted.
The standard industry response to European access difficulty has been sequencing — de-prioritise the markets where the price anchor is lowest and launch there last, or not at all. That logic is being eroded from both directions simultaneously: JCA is standardising evidence requirements across markets (making it harder to manage country-by-country), while MFN is making the price you accept in your lowest-anchor market directly relevant to your most important revenue stream.
A term sheet built for a world that no longer exists
A term sheet built for a world that no longer exists
A mid-size oncology company in late-stage out-licensing discussions has structured its European deal on assumptions that were commercially reasonable eighteen months ago: tiered royalties by market, with Germany and France as anchor references, and the US deal negotiated independently on clinical merit. Forward modelling now shows that the European pricing corridor implied by the term sheet — if accepted — would sit inside the GLOBE reference basket for the relevant therapeutic class. The damage is not yet realised — but the structure that created it is locked. The European deal was optimised for the world that existed when it was signed. That world has changed.
This is not a failure of execution. It is a failure of framing — treating European access strategy and US commercial strategy as independent workstreams when they are now the same workstream running on different timelines.
The Dupixent counterpoint — and why it does not generalise
The standard counterargument is Dupixent: a blockbuster with strong EU uptake, strong US pricing, and no apparent MFN vulnerability. The counterpoint is valid for what it is. It is not a generalisation. Dupixent benefits from an evidence base of unusual depth and breadth, a therapeutic positioning that commanded premium pricing in every market independently, and a launch sequence that predates the current MFN architecture by several years.
For the majority of assets currently in Phase 2 and Phase 3 development — particularly in oncology, rare disease, and advanced therapies — the conditions that made Dupixent resilient do not apply. The evidence packages are thinner. The competitive landscapes are more crowded. The pricing corridors are narrower. And the MFN mechanisms that were not yet active when Dupixent launched are now operational.
The question is not whether Dupixent proves MFN is manageable. The question is whether your asset looks more like Dupixent or more like the assets that will not survive the new pricing environment intact.
What this means for decisions being made now
The decisions with the most leverage — evidence strategy, launch sequencing, deal structure, pricing corridor — are being made in Phase 2 and Phase 3, years before launch. By the time a commercial team is negotiating a European reimbursement submission, most of the structural choices that determine the outcome have already been made.
- Is your evidence package being designed to the JCA comparative effectiveness standard, or to the national HTA standard of your lead market?
- Does your deal structure — licensing, co-commercialisation, or royalty — account for the MFN transmission mechanism between European reference price and US Medicare ceiling?
- Does your launch sequence reflect the new risk hierarchy, or the one that existed three years ago?
The companies that navigate this environment well are not the ones with the best lawyers or the fastest regulatory teams. They are the ones that understood, early enough, that EU access strategy and US pricing strategy had become the same problem — and built the evidence and commercial architecture accordingly.
The exposure is not waiting for a strategic decision to be made about Europe's priority. It is already running.